Skip to main content

Janire Perurena Prieto

Institutions of which they are part

Predoctoral researcher
Translational Immunology
Vall Hebron Institut de Recerca

Janire Perurena Prieto

Institutions of which they are part

Predoctoral researcher
Translational Immunology
Vall Hebron Institut de Recerca

Projects

La interacción entre el error innato de la inmunidad y los trastornos sanguíneos: desentrañando los defectos inmunitarios detrás de las enfermedades hematológicas comunes

IP: Pere Soler Palacín
Collaborators: Laura Batlle Masó, Maria Cristina Díaz de Heredia Rubio, Roger Colobran Oriol, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Miriam Gonzalez Amores, Janire Perurena Prieto, Andrea Martín Nalda, Lucas Moreno Martín-Retortillo, Jacques Gabriel Rivière
Funding agency: Instituto de Salud Carlos III
Funding: 179993.75
Reference: AC23_2/00033
Duration: 01/01/2024 - 31/12/2026

Optimización del test de deposición ex vivo de C5b9 para monitorizar la actividad y la respuesta al tratamiento en SHUa y otras glomerulopatías complejas

IP: Concepció Jacobs Cachá
Collaborators: Manuel Hernández González, Natalia Ramos Terrades, Joana Sellarés Roig, Carmen Llorens Cebriá, Janire Perurena Prieto
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 24000
Reference: SENEFRO/PROJECTES/2023/JACOBS
Duration: 23/12/2023 - 22/12/2025

Estudio de expresión de antígenos en tejido tumoral de pacientes con Esclerosis Sistémica.

IP: Alfredo Guillen Del Castillo
Collaborators: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla, Maria Roca Herrera, Janire Perurena Prieto, Irene Sansano Valero
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01804
Duration: 01/01/2023 - 31/12/2025

OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE ANTÍGENO QUIMÉRICO (CAR-T)

IP: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE
Collaborators: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE , Gloria Inés Iacoboni García-Calvo, Maria Queralt Gorgas Torner, Lucas Rivera Sánchez, Anna Maria Farriols Danes, Pere Barba Suñol, Carla Alonso Martinez, Janire Perurena Prieto, Maria Josep Carreras Soler, Cecilia Carmen Carpio Segura
Funding agency: Instituto de Salud Carlos III
Funding: 111320
Reference: PI21/00197
Duration: 01/01/2022 - 31/12/2024

Related news

A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

Related professionals

Arantxa Ibarz Casas

Arantxa Ibarz Casas

Research technician
Research Group of Physical Medicine and Rehabilitation
Read more
Maria Pallares Masmitja

Maria Pallares Masmitja

Postdoctoral researcher
Gene Therapy at Nervous System
Read more
Josep Masramon Puig

Josep Masramon Puig

Research technician
Rheumatology
Read more
Silvia Soler García

Silvia Soler García

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.